Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer

Дата публикации: 25-06-2026 00:00:00

The treatment of early-stage human epidermal growth factor receptor 2 (ERBB2; previously HER2)–positive breast cancer has changed profoundly over the past 3 decades. A disease once defined by aggressive behavior is now often curable, largely because ERBB2-directed therapy has been successfully combined with chemotherapy. This progress has changed the question that clinicians and patients face. For many patients, the issue is no longer only how much treatment is required to prevent recurrence but how much treatment can be safely avoided.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
2	Team finds way to reverse ovarian cancer’s chemo resistance	5	8	25-06-2026
3	Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors	0	7	25-06-2026
4	Survival in the SONIA Trial	0	7	18-06-2026
5	Survival in the SONIA Trial	0	8	18-06-2026
6	Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy	0	7	18-06-2026
7	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
8	Центр компетенций НТИ создаст инновационные препараты для лечения рака	0	0	22-08-2019
9	Почему рак легкого так сложно распознать	0	0	19-08-2019
10	Российские ученые разрабатывают имплантант для борьбы с раком мозга	0	0	21-08-2019

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.